Search Results for: CDK2

161 interactions involving CDK2 - cyclin dependent kinase 2 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
BRCA2 BRCA2 DNA repair associated
  • HDR through MMEJ (alt-NHEJ)
  • HDR through Homologous Recombination (HRR)
  • Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
  • Resolution of D-loop Structures through Holliday Junction Intermediates
  • Homologous DNA Pairing and Strand Exchange
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Defective homologous recombination repair (HRR) due to BRCA1 loss of function
  • Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
  • Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
  • Impaired BRCA2 translocation to the nucleus
  • Impaired BRCA2 binding to RAD51
  • Impaired BRCA2 binding to PALB2
  • Impaired BRCA2 binding to SEM1 (DSS1)
  • Ovarian cancer
  • Fanconi anemia
  • Breast cancer
  • Pancreatic cancer
BTBD2 BTB domain containing 2
CBY2 chibby family member 2
CCNA1 cyclin A1
  • G0 and Early G1
  • Telomere Extension By Telomerase
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Ub-specific processing proteases
  • Processing of DNA double-strand break ends
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • G2 Phase
  • Orc1 removal from chromatin
  • CDK-mediated phosphorylation and removal of Cdc6
  • G1/S-Specific Transcription
  • Cyclin A/B1/B2 associated events during G2/M transition
  • G2/M DNA replication checkpoint
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
CCNA2 cyclin A2
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • G0 and Early G1
  • Telomere Extension By Telomerase
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Ub-specific processing proteases
  • Processing of DNA double-strand break ends
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • G2 Phase
  • Orc1 removal from chromatin
  • CDK-mediated phosphorylation and removal of Cdc6
  • Cyclin A/B1/B2 associated events during G2/M transition
  • G2/M DNA replication checkpoint
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • 6-O-Cyclohexylmethyl Guanine
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine
  • 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • Variolin B
CCNB2 cyclin B2
  • Polo-like kinase mediated events
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Resolution of Sister Chromatid Cohesion
  • Condensation of Prometaphase Chromosomes
  • Regulation of PLK1 Activity at G2/M Transition
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Initiation of Nuclear Envelope (NE) Reformation
  • Nuclear Pore Complex (NPC) Disassembly
  • Cyclin A/B1/B2 associated events during G2/M transition
  • G2/M DNA replication checkpoint
  • The role of GTSE1 in G2/M progression after G2 checkpoint
CCNB3 cyclin B3
CCNE1 cyclin E1
  • G0 and Early G1
  • SCF(Skp2)-mediated degradation of p27/p21
  • DNA Damage/Telomere Stress Induced Senescence
  • Association of TriC/CCT with target proteins during biosynthesis
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • G1/S-Specific Transcription
  • Cyclin D associated events in G1
  • p53-Dependent G1 DNA Damage Response
  • PTK6 Regulates Cell Cycle
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • RHOBTB3 ATPase cycle
  • Laryngeal cancer
  • Gastric cancer
CCNE2 cyclin E2
  • G0 and Early G1
  • SCF(Skp2)-mediated degradation of p27/p21
  • DNA Damage/Telomere Stress Induced Senescence
  • Association of TriC/CCT with target proteins during biosynthesis
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • p53-Dependent G1 DNA Damage Response
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Laryngeal cancer
  • Gastric cancer
CCNH cyclin H
  • Formation of RNA Pol II elongation complex
  • Formation of the Early Elongation Complex
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Tat-mediated elongation of the HIV-1 transcript
  • NoRC negatively regulates rRNA expression
  • Formation of Incision Complex in GG-NER
  • RNA Polymerase II Pre-transcription Events
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of DNA Repair Genes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • mRNA Capping
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Pol II CTD phosphorylation and interaction with CE
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
CCNK cyclin K
  • Formation of RNA Pol II elongation complex
  • Formation of HIV elongation complex in the absence of HIV Tat
  • HIV elongation arrest and recovery
  • Pausing and recovery of HIV elongation
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • RNA Polymerase II Pre-transcription Events
  • TP53 Regulates Transcription of DNA Repair Genes
  • RNA polymerase II transcribes snRNA genes
  • RNA polymerase II transcribes snRNA genes
  • RNA Polymerase II Transcription Elongation
CCP110 centriolar coiled-coil protein 110
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • Ub-specific processing proteases
  • AURKA Activation by TPX2
  • RHOV GTPase cycle
CDC25A cell division cycle 25A
  • Transcription of E2F targets under negative control by DREAM complex
  • Polo-like kinase mediated events
  • Activation of ATR in response to replication stress
  • Ub-specific processing proteases
  • Cyclin E associated events during G1/S transition
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • Cyclin A:Cdk2-associated events at S phase entry
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
CDC25B cell division cycle 25B
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • L-cysteic acid
CDC25C cell division cycle 25C
  • Polo-like kinase mediated events
  • Activation of ATR in response to replication stress
  • RHO GTPases activate PKNs
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
CDC37 cell division cycle 37, HSP90 cochaperone
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Constitutive Signaling by EGFRvIII
  • Regulation of necroptotic cell death
  • Downregulation of ERBB2 signaling
  • RHOBTB2 GTPase cycle
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
CDC5L cell division cycle 5 like
  • mRNA Splicing - Major Pathway
CDC6 cell division cycle 6
  • Transcription of E2F targets under negative control by DREAM complex
  • Activation of ATR in response to replication stress
  • CDC6 association with the ORC:origin complex
  • Assembly of the pre-replicative complex
  • Orc1 removal from chromatin
  • Activation of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • G1/S-Specific Transcription
CDC7 cell division cycle 7
  • Activation of ATR in response to replication stress
  • Activation of the pre-replicative complex
  • Transcriptional Regulation by E2F6
CDK20 cyclin dependent kinase 20

Page 2 out of 9 pages